Aug 30, 2023 | Dermatology Practice, Pathology Business, Press Release
The leader in digital dermatopathology is recognized in the Health Services category of the prestigious list.
SALT LAKE CITY—August 15, 2023—Today, Inc. named PathologyWatch in the top 7 percent of America’s fastest-growing private companies on the annual Inc. 5000 list. This marks the first appearance on the list for the deep-learning AI company, which focuses on diagnostic and prognostic research for skin cancer.
Founded in 2017, PathologyWatch reached number 386 on the list of 5,000 companies for showcasing a remarkable 1500 percent growth from 2019 to 2022. This achievement makes PathologyWatch the list’s top-ranked health services company based in Utah.
“It’s an incredible honor to have PathologyWatch recognized alongside so many notable companies on the Inc. 500 list,” said Dan Lambert, CEO and cofounder of PathologyWatch. “This acknowledgment is a testament to the perseverance and principles of our entire organization, including AI engineers, dermatopathologists, lab technicians, sales and marketing team, clients and everyone in between. Together, we’ve been able to continue our commitment to combine state-of-the-art technology and clinical decision-making to deliver unprecedented patient care.”
The ongoing prevalence of skin cancer in the United States is a driver in the demand for PathologyWatch’s comprehensive digital dermatopathology solutions. There are over 5 million cases of skin cancer detected every year in America, killing more than two people every hour and making it the country’s most common type of cancer.
Lambert, a melanoma survivor, noted, “This Inc 500 recognition reinforces our mission to preserve and extend life for patients while reducing the cost of healthcare.”
“Running a business has only gotten harder since the end of the pandemic,” said Inc. editor-in-chief Scott Omelianuk. “To make the Inc. 5000 — with the fast growth that it requires — is truly an accomplishment. Inc. is thrilled to honor the companies that are building our future.”
About PathologyWatch
PathologyWatch is the groundbreaking leader of digital dermatopathology services. Through these services, dermatology clinics, hospitals and laboratories can improve operational efficiency by speeding up workflow and enhancing patient outcomes by utilizing the PathologyWatch expert professional team and laboratory services. This can facilitate best-in-class reads and, in some cases, enable additional revenue to the practice by in-housing pathology. With an intuitive and easy-to-implement digital pathology solution that includes access to top-tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR, PathologyWatch brilliantly combines state-of-the-art technology and clinical decision-making to deliver unprecedented patient care.
May 3, 2023 | Dermatology Practice, Press Release
SALT LAKE CITY—May 1, 2023—PathologyWatch, a full-service digital dermatopathology solution, is recognizing May as Melanoma and Skin Cancer Awareness Month with a public awareness campaign of its own.
Many Americans are likely unaware of just how prevalent skin cancer is in the US. In conjunction with Melanoma and Skin Cancer Awareness Month, the Skin Cancer Foundation has released some sobering statistics about the disease:
- With over 5 million cases detected each year in the US, skin cancer is the most common form of cancer.
- More than two people die from skin cancer every hour in the US.
- More people are diagnosed with skin cancer each year in the US than all other cancers combined.
- An estimated 7,990 people will die from melanoma in 2023 (5,420 men and 2,570 women).
- An estimated 186,680 cases of melanoma will be diagnosed in the US in 2023.
- One in five Americans will be diagnosed with skin cancer by the age of 70.
“One other key statistic is that the five-year survival rate for melanoma, when it is detected early, is 99 percent,” said Dan Lambert, CEO of PathologyWatch. “That’s why, during the month of May and beyond, we are encouraging everyone to visit their physician or dermatologist and receive an examination. Our mission at PathologyWatch is to preserve and extend life for patients while reducing the cost of healthcare. Early detection is one way we’re working to achieve that goal.”
PathologyWatch uses cutting-edge technology to connect dermatologists with academic-level dermatopathologists in a workflow utilizing samples shared via digital slides. The full-system digital workflow not only optimizes efficiency but also saves physician time, reduces the burden on office staff, and can help clinics create previously untapped revenue streams.
The Utah-based company will be providing “Show Me Some Skin” T-shirts to dermatologists and dermatopathologists who participate in the upbeat awareness campaign. Dermatologists and dermpaths can receive their free T-shirt by simply registering to join the campaign.
“We feel this is a fun way for dermatologists to help get the word out this month about a serious health issue,” Lambert said. “The most important thing in the fight against skin cancer is for people to take the initiative to get tested. May offers the perfect opportunity to commit to that first step.”
About PathologyWatch
PathologyWatch is the groundbreaking leader of digital dermatopathology services. Through these services, dermatology clinics, hospitals and laboratories can improve operational efficiency by speeding up workflow and enhancing patient outcomes by utilizing the PathologyWatch expert professional team and laboratory services. This can facilitate best-in-class reads and, in some cases, enable additional revenue to the practice by in-housing pathology. With an intuitive and easy-to-implement digital pathology solution that includes access to top-tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR, PathologyWatch brilliantly combines state-of-the-art technology and clinical decision-making to deliver unprecedented patient care.
Apr 19, 2023 | Press Release
New partnership will manage pathology workflows using a digital model
Omaha, Nebraska – The University of Nebraska Medical Center/Nebraska Medicine Department of Dermatology announced a partnership with PathologyWatch, a full-service pathology laboratory combining revolutionary digital technology with expert dermatopathology services to provide patients and doctors with an accurate and timely diagnosis. This new service aims to give Nebraska Medicine patients faster diagnoses and access to dermatopathologists anywhere.
“We are ecstatic at the med center to be partnered with PathologyWatch, experts in digital dermatopathology and artificial intelligence, to expand access to high-quality dermatopathology in our region,” said Ashley Wysong, MD, chair of the UNMC Department of Dermatology. “Specifically, dermatologists and primary care physicians will have access to our board-certified and fellowship-trained dermatopathologists at UNMC and PathologyWatch to improve patient care and diagnostic accuracy with quick specimen turnaround, digital images of skin biopsies integrated directly into electronic medical records, and opportunities to discuss challenging cases and clinicopathologic correlations with our dermatology-trained dermatopathologists. We are energized by this partnership with PathologyWatch and see many great things to come.”
Features and benefits of PathologyWatch include:
- Patient biopsies are prepared on slides and digitized;
- Dermatopathologists can read and interpret each specimen digitally ;
- Detailed reports are delivered electronically; and
- Dermatologists have quick access to communicate with dermatopathologists on interpretations.
Corey Georgesen, MD, assistant professor and director of dermatopathology at UNMC, will be the dermatopathologist entering the program. Dr. Georgesen is a board-certified and fellowship trained dermatologist, dermatopathologist and telemedicine specialist with Nebraska roots and diverse training experience. He will be working in collaboration with April Larson, MD, chief medical officer of PathologyWatch.
“This collaboration will foster forward-thinking and innovative diagnostic techniques for patients in the Nebraska and Midwest community,” Dr. Georgesen said. “Working together, we will utilize technological advances to analyze skin biopsies. Our symbiosis undoubtedly will translate into a model that will become a beacon for excellent and effective patient care. The future is bright.”
“We are very excited about this partnership,” Dr. Larson said. “Our goal to make life-saving diagnostic technology accessible and affordable is advanced in a meaningful way with our affiliation with the UNMC team. We are proud to partner with this state-of-the-art organization and look forward to providing these important services in the Nebraska area.”
For more information about PathologyWatch, visit pathologywatch.com or email. For media inquiries, contact Amy Cook at 949-813-0182 or via email.
To schedule a demo, contact Aaron Christensen via email.
###
About UNMC and Nebraska Medicine
We are Nebraska Medicine and UNMC. Our mission is to lead the world in transforming lives to create a healthy future for all individuals and communities through premier educational programs, innovative research and extraordinary patient care.
About PathologyWatch
PathologyWatch is the groundbreaking leader of digital dermatopathology services. Through these services, dermatology clinics, hospitals and laboratories can improve operational efficiency by speeding up workflow and enhancing patient outcomes by utilizing the PathologyWatch expert professional team and laboratory services. This can facilitate best-in-class reads and, in some cases, enable additional revenue to the practice by in-housing pathology. With an intuitive and easy-to-implement digital pathology solution that includes access to top-tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR, PathologyWatch brilliantly combines state-of-the-art technology and clinical decision-making to deliver unprecedented patient care.
Jul 29, 2022 | Press Release
Cacey Peters, MD, joins the PathologyWatch team to strengthen the delivery of optimal patient outcomes.
SALT LAKE CITY—JULY 29, 2022—PathologyWatch, a leader in digital dermpath services, is pleased to welcome Dr. Cacey Peters, MD, to its clinical team. A skillful dermatopathologist, Dr. Peters’ enthusiasm and proficiency in digital pathology make him a natural fit with PathologyWatch’s objective to provide dermatologists with better patient care.
“Combining diagnostic and communication skills with a vast knowledge of whole-slide imaging, Dr. Peters represents a valuable addition to our team of expert dermatopathologists,” says Dan Lambert, cofounder and chief executive officer of PathologyWatch.
Dr. Peters completed his residency in anatomic and clinical pathology at Tulane. His fellowship was in dermatopathology at the Ackerman Academy of Dermatopathology, and he is US-board certified in dermatopathology, anatomic and clinical pathology.
“Streamlining the diagnosis, turnaround time and overall efficiency for dermatologists is crucial to me,” said Dr. Peters. “Joining PathologyWatch will help me to deliver on these goals while also contributing to the team of talented dermatopathologists on challenging cases to benefit the clinicians we serve.”
Dr. Peters comes to PathologyWatch with years of experience promoting digital pathology as a tool to unite and educate both dermatologists and pathologists around the world. “Switching over to primary diagnosis on a digital platform is a dream come true,” said Dr. Peters. “Within my lifetime, I’ve no doubt digital pathology will take over 100% of the industry.”
For more information, please email [email protected] or visit pathologywatch.com.
About PathologyWatch
PathologyWatch is the groundbreaking leader of digital dermatopathology services. Through these services, dermatology clinics, hospitals and laboratories can improve operational efficiency by speeding up workflow and enhancing patient outcomes by utilizing the PathologyWatch expert professional team and laboratory services. This can facilitate best-in-class reads and, in some cases, enable additional revenue to the practice by in-housing pathology. With an intuitive and easy-to-implement digital pathology solution that includes access to top-tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR, PathologyWatch brilliantly combines state-of-the-art technology and clinical decision-making to deliver unprecedented patient care.
Jan 6, 2022 | Dermatopathology Lab, Pathology Business, Press Release, Uncategorized
The Series B funding round will help PathologyWatch digitize biopsies, increase access to top skincare physicians and further AI research.
SALT LAKE CITY, November 16, 2021—PathologyWatch, the leading digital lab and pathology platform for dermatologists, announced today that it has raised $25M in Series B financing with participation from Ceros Capital Markets, Rock Creek Capital, SpringTide, Spark Growth Ventures, Blueprint Health, Blackbrook Management Group and existing investors.
With the new funding, PathologyWatch will broaden its outreach to dermatologists and conduct further research into skincare diagnostics and AI – allowing patients to receive faster diagnoses and more equitable access to dermatopathology services while enabling labs to work more efficiently and cost-effectively. Additionally, the funding will support operations as the business expands across the country, adding new labs in Texas, Florida and Arizona.
“We are honored that of all the digital dermpath labs available, dermatologists are increasingly choosing to partner with us,” said Dan Lambert, PathologyWatch CEO and cofounder. “As digital dermatopathology continues to grow, it has the potential to reduce the costs of pathology by billions while creating better patient care for everyone across the country. We’re thrilled to be winning so much volume so quickly.”
PathologyWatch provides fully interfaced EMR reporting and 24/7 access to digital slides for dermatology clinics. For their clients, this means more-efficient workflows and direct access to leading dermatopathologists across the country, with broad insurance coverage. PathologyWatch has successfully integrated laboratory information systems, scanners, digital viewer technology and EMRs into an end-to-end solution for dermatologists.
“PathologyWatch has been disruptive to the market and is digitally transforming the industry in unprecedented ways,” said Mark Goldwasser, CEO of Ceros. “With the need for remote health services during COVID, the distributed network of top-tier dermatopathologists alongside a digital viewer that can be accessed anytime and anywhere could not have come at a more fortuitous time.”
“For a dermatology practice to send nearly all skin biopsy volume for cancer diagnosis to PathologyWatch is a no-brainer,” said Austin Walters, founder and managing partner at SpringTide. “The company has worked hard to create a service that outperforms every other from both cost and quality perspectives.”
“Dan is a driven entrepreneur with social good in mind,” said Ryan Brooks, principal at Blackbrook Management Group. “We are part of a cause, not just an investment capital endeavor. In the past, I have been a patient waiting for pathology to come back. When you are waiting for results that could change your life dramatically, you want doctors and tech you can depend on. PathologyWatch will enhance the human experience and enable dermatopathologists to do a better job.”
“I am proud to support PathologyWatch’s mission to provide premier, accessible and affordable digital pathology services to the world,” said Rick Stratford, managing director of Rock Creek Capital. “The ability to provide top-tier pathology services to all communities regardless of location brings hope to patients in underserved areas and can save countless lives. PathologyWatch and other digital platforms like it are democratizing healthcare services and bringing hope and change to our healthcare systems.”
For more information about PathologyWatch, visit pathologywatch.com or contact [email protected].
About PathologyWatch
PathologyWatch is the groundbreaking leader of digital dermatopathology services. Through these services, dermatology clinics, hospitals and laboratories can improve operational efficiency by speeding up workflow and enhancing patient outcomes by utilizing the PathologyWatch expert professional team and in-house lab services. With an intuitive and easy-to-implement digital pathology solution that includes access to top-tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR, PathologyWatch brilliantly combines state-of-the-art technology and clinical decision-making to deliver unprecedented patient care.
May 7, 2021 | Digital Dermatopathology, Pathology Business, Press Release
A leader in dermatology and dermatopathology, Allison Readinger, MD, joins PathologyWatch’s clinical team to assist in the growing landscape of digital healthcare.
Salt Lake City—March 7, 2021—PathologyWatch, a full-service digital pathology service, is pleased to welcome Allison Readinger, MD, to its clinical team. A highly qualified and respected dermatologist and dermatopathologist, Readinger brings a wealth of industry knowledge and innovation, coinciding with PathologyWatch’s mission to preserve and extend life for patients while reducing healthcare costs.
“We are pleased to have Dr. Readinger join us as a member of our clinical team. Her industry expertise and seasoned leadership skills make her a genuine asset,” said Dan Lambert, cofounder and chief executive officer of PathologyWatch. “Together, we are eager to expand our reach across the Texas market, positively impacting the lives of our healthcare providers and their patients.”
An alumnus of the University of Texas Medical Branch at Galveston, Readinger is a board-certified dermatologist and dermatopathologist with over 15 years of experience. In October 2010, she opened Trinity Vista Dermatology to offer more dermatology services to the rapidly growing population of Fort Worth, Texas.
Readinger recently served as President of the Texas Dermatological Society and continues to advocate for patients, for physician and resident education, and for her specialty.
At her core, Readinger enjoys bonding with her patients, providing excellent care, and being at the forefront of advances in medical technology. With an understanding of the importance of attention to detail and personalized care in modern medicine, she makes an excellent addition to the PathologyWatch family.
“I am thrilled to be a part of the continued growth of digital dermatopathology,” said Readinger. “The landscape of digital dermatopathology is growing at a rapid pace, and I am eager to assist in the continued growth and progress of our field.” She adds, “I hope to utilize digital dermatopathology to expand further my ability to offer great clinicopathologic correlation to my clients.”
For more information, please email [email protected] or visit us at pathologywatch.com.
About PathologyWatch
PathologyWatch is the groundbreaking leader of digital dermatopathology services. Through these services, dermatology clinics, hospitals and laboratories can improve operational efficiency by speeding up workflow and enhancing patient outcomes by utilizing the PathologyWatch expert professional team and partner laboratory services. This can facilitate best-in-class reads and, in some cases, enable additional revenue to the practice by in-housing pathology. With an intuitive and easy-to-implement digital pathology solution that includes access to top-tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR, PathologyWatch brilliantly combines state-of-the-art technology and clinical decision-making to deliver unprecedented patient care.
